WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 200750
CAS#: 206991-64-2 (HCl)
Description: CGC-11047 is a second generation polyamine analogue, synthesized through the restriction of molecular conformations of parent polyamine compounds, with potential antineoplastic activity. Polyamine analogue PG11047 may displace endogenous polyamines from DNA binding sites, thereby interfering with cell cycle processes dependent upon polyamine binding and function, and resulting in cell-cycle arrest, induction of apoptosis, depletion of polyamines, and interference with gene and ligand-receptor activities involved with cell growth. This agent may exhibit decreased toxicity and enhanced cytotoxicity profiles compared to first-generation polyamine compounds. In tumor cells, there is an increase dependence on polyamines as well as a dysregulated polyamine metabolic pathway resulting in abnormal or sustained tumor growth.
MedKoo Cat#: 200750
Name: CGC-11047 HCl
CAS#: 206991-64-2 (HCl)
Chemical Formula: C14H36Cl4N4
Exact Mass: 256.2627
Molecular Weight: 402.27444
Elemental Analysis: C, 41.80; H, 9.02; Cl, 35.25; N, 13.93
CGC-11047, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Related CAS #: 308145-19-9 (free base) 206991-64-2 (HCl)
Synonym: CGC 11047; CGC-11047; CGC11047; CGC-11047 hydrochloride ; SL 11047; SL11047; SL-11047; SL 47; PG11047; PG-11047.
IUPAC/Chemical Name: (Z)-N1,N1'-(but-2-ene-1,4-diyl)bis(N3-ethylpropane-1,3-diamine) tetrahydrochloride
InChi Key: MNJCMBNLXQCNHO-YGGCHVFLSA-N
InChi Code: InChI=1S/C14H32N4.4ClH/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2;;;;/h5-6,15-18H,3-4,7-14H2,1-2H3;4*1H/b6-5-;;;;
SMILES Code: CCNCCCNC/C=C\CNCCCNCC.[H]Cl.[H]Cl.[H]Cl.[H]Cl
The following data is based on the product molecular weight 402.27444 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Dredge K, Kink JA, Johnson RM, Bytheway I, Marton LJ. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother Pharmacol. 2009 Dec;65(1):191-5. doi: 10.1007/s00280-009-1105-7. Epub 2009 Aug 15. PubMed PMID: 19685053.
2: Hacker A, Marton LJ, Sobolewski M, Casero RA Jr. In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008 Dec;63(1):45-53. doi: 10.1007/s00280-008-0706-x. Epub 2008 Feb 27. PubMed PMID: 18301893.
3: Mitchell JL, Thane TK, Sequeira JM, Marton LJ, Thokala R. Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids. 2007 Aug;33(2):291-7. Epub 2007 Apr 6. PubMed PMID: 17410332.
4: Lima e Silva R, Kachi S, Akiyama H, Shen J, Hatara MC, Aslam S, Gong YY, Khu NH, Lauer TW, Hackett SF, Marton LJ, Campochiaro PA. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res. 2006 Nov;83(5):1260-7. Epub 2006 Sep 6. PubMed PMID: 16950258.
5: Loussouarn G, Marton LJ, Nichols CG. Molecular basis of inward rectification: structural features of the blocker defined by extended polyamine analogs. Mol Pharmacol. 2005 Aug;68(2):298-304. Epub 2005 May 4. PubMed PMID: 15872118.
